GRANT PICKERING - 21 Sep 2021 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Chief Executive Officer, Director
Signature
/s/ Ron Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
21 Sep 2021
Net transactions value
-$351,375
Form type
4
Filing time
23 Sep 2021, 17:40:03 UTC
Previous filing
25 Aug 2021
Next filing
22 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $19,345 +10,807 +1.9% $1.79* 591,061 21 Sep 2021 Direct
transaction PCVX Common Stock Sale $251,826 -10,005 -1.7% $25.17 581,056 21 Sep 2021 Direct F1, F2
transaction PCVX Common Stock Sale $20,764 -802 -0.14% $25.89 580,254 21 Sep 2021 Direct F1, F3
transaction PCVX Common Stock Options Exercise $7,505 +4,193 +0.72% $1.79* 584,447 22 Sep 2021 Direct
transaction PCVX Common Stock Sale $105,636 -4,193 -0.72% $25.19 580,254 22 Sep 2021 Direct F1, F4
holding PCVX Common Stock 355,660 21 Sep 2021 By Children's Trusts

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -10,807 -2.9% $0.000000 363,008 21 Sep 2021 Common Stock 10,807 $1.79 Direct F5
transaction PCVX Stock Option (right to buy) Options Exercise $0 -4,193 -1.2% $0.000000 358,815 22 Sep 2021 Common Stock 4,193 $1.79 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $24.73 to $25.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $25.88 to $25.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $24.90 to $25.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 The shares subject to the option are fully vested and exercisable.